司美格鲁肽 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "司美格鲁肽" in Chinese language version.

refsWebsite

Global rank Chinese rank

26web.archive.org

1^st place

19nih.gov

4^th place

5^th place

9worldcat.org

5^th place

12^th place

9doi.org

2^nd place

23^rd place

3tga.gov.au

3,984^th place

1,603^rd place

3europa.eu

68^th place

209^th place

3hres.ca

low place

2funnelback.com

low place

2medicines.org.uk

3,823^rd place

3,456^th place

1jjq.gov.cn

low place

1peptideshop.online

low place

1chinacdc.cn

low place

3,740^th place

1nature.com

234^th place

227^th place

1rxlist.com

7,927^th place

5,088^th place

1who.int

195^th place

179^th place

chinacdc.cn

literature.chinacdc.cn

中国疾病预防控制中心. 华人团队发现，“减肥神药”司美格鲁肽或可显著降低阿尔茨海默病风险. 中国疾病预防控制中心科技文献服务系统. 2024-11-26 [2025-05-12]. （原始内容存档于2024-12-12）.

doi.org

Bliddal, Henning; Bays, Harold; Czernichow, Sébastien; Uddén Hemmingsson, Joanna; Hjelmesæth, Jøran; Hoffmann Morville, Thomas; Koroleva, Anna; Skov Neergaard, Jesper; Vélez Sánchez, Patricia; Wharton, Sean; Wizert, Alicja. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine. 2024-10-31, 391 (17) [2025-05-12]. ISSN 1533-4406. PMID 39476339. doi:10.1056/NEJMoa2403664. （原始内容存档于2025-03-17）.
Wang, Lindsey; Xu, Rong; Kaelber, David C.; Berger, Nathan A. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA network open. 2024-07-01, 7 (7) [2025-05-12]. ISSN 2574-3805. PMC 11227080 . PMID 38967919. doi:10.1001/jamanetworkopen.2024.21305. （原始内容存档于2025-02-20）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024-05-28, 15 (1) [2025-05-12]. ISSN 2041-1723. PMC 11133479 . PMID 38806481. doi:10.1038/s41467-024-48780-6. （原始内容存档于2025-04-15）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiatry. 2024-08, 29 (8) [2025-05-12]. ISSN 1476-5578. PMC 11412894 . PMID 38486046. doi:10.1038/s41380-024-02498-5. （原始内容存档于2025-02-23）.
Apperloo, Ellen M.; Gorriz, Jose L.; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M.; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D.; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nature Medicine. 2025-01, 31 (1) [2025-05-12]. ISSN 1546-170X. doi:10.1038/s41591-024-03327-6. （原始内容存档于2025-04-30）（英语）.
Wang, William; Wang, QuangQiu; Qi, Xin; Gurney, Mark; Perry, George; Volkow, Nora D.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2024-12, 20 (12) [2025-05-12]. ISSN 1552-5279. PMC 11667504 . PMID 39445596. doi:10.1002/alz.14313. （原始内容存档于2025-05-03）.
Sanyal, Arun J.; Newsome, Philip N.; Kliers, Iris; Østergaard, Laura Harms; Long, Michelle T.; Kjær, Mette Skalshøi; Cali, Anna M. G.; Bugianesi, Elisabetta; Rinella, Mary E.; Roden, Michael; Ratziu, Vlad. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England Journal of Medicine. 2025-04-30 [2025-05-12]. ISSN 1533-4406. PMID 40305708 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2413258.
McGuire, Darren K.; Marx, Nikolaus; Mulvagh, Sharon L.; Deanfield, John E.; Inzucchi, Silvio E.; Pop-Busui, Rodica; Mann, Johannes F. E.; Emerson, Scott S.; Poulter, Neil R.; Engelmann, Mads D. M.; Ripa, Maria Sejersten. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025-03-29 [2025-05-12]. ISSN 1533-4406. PMID 40162642 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2501006. （原始内容存档于2025-04-04）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024-01, 30 (1) [2025-05-12]. ISSN 1546-170X. PMC 11034947 . PMID 38182782. doi:10.1038/s41591-023-02672-2.

europa.eu

ema.europa.eu

Ozempic EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-09-26]. （原始内容存档于2020-10-25）.
Rybelsus EPAR. European Medicines Agency (EMA). 2020-01-29 [2020-09-26]. （原始内容存档于2020-08-14）.
Wegovy EPAR. European Medicines Agency. 2021-11-11 [2022-03-11]. （原始内容存档于2022-07-02）.

funnelback.com

tga-search.clients.funnelback.com

Summary for ARTG Entry:315107 Ozempic 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen. Therapeutic Goods Administration (TGA). [2021-06-06]. （原始内容存档于2022-02-24）.
Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack. Therapeutic Goods Administration (TGA). [2022-02-23]. （原始内容存档于2022-02-24）.

hres.ca

pdf.hres.ca

Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (报告). Novo-Nordisk Canada. 2020-08-21 [Initial approval 4 January 2018] [2021-06-06]. （原始内容存档 (PDF)于2021-06-07）.
Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (报告). Novo-Nordisk Canada. 2020-03-30 [2021-06-06]. （原始内容存档 (PDF)于2021-12-14）.

hpr-rps.hres.ca

Regulatory Decision Summary – Rybelsus. Health Canada. 2014-10-23 [2022-06-04]. （原始内容存档于2022-06-05）.

jjq.gov.cn

鸠江区科学技术局（科协）. 世界上从来没有“减肥神药”. 鸠江区人民政府. 2024-06-28 [2024-11-18] –通过芜湖市政务公开平台（中文）. ^{[失效連結]}

medicines.org.uk

Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC). (emc). 2021-04-09 [2021-06-06]. （原始内容存档于2021-06-06）.
Rybelsus – Summary of Product Characteristics (SmPC). (emc). 2020-11-25 [2021-06-06]. （原始内容存档于2021-06-06）.

nature.com

Apperloo, Ellen M.; Gorriz, Jose L.; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M.; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D.; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nature Medicine. 2025-01, 31 (1) [2025-05-12]. ISSN 1546-170X. doi:10.1038/s41591-024-03327-6. （原始内容存档于2025-04-30）（英语）.

nih.gov

pubmed.ncbi.nlm.nih.gov

Bliddal, Henning; Bays, Harold; Czernichow, Sébastien; Uddén Hemmingsson, Joanna; Hjelmesæth, Jøran; Hoffmann Morville, Thomas; Koroleva, Anna; Skov Neergaard, Jesper; Vélez Sánchez, Patricia; Wharton, Sean; Wizert, Alicja. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine. 2024-10-31, 391 (17) [2025-05-12]. ISSN 1533-4406. PMID 39476339. doi:10.1056/NEJMoa2403664. （原始内容存档于2025-03-17）.
Wang, Lindsey; Xu, Rong; Kaelber, David C.; Berger, Nathan A. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA network open. 2024-07-01, 7 (7) [2025-05-12]. ISSN 2574-3805. PMC 11227080 . PMID 38967919. doi:10.1001/jamanetworkopen.2024.21305. （原始内容存档于2025-02-20）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024-05-28, 15 (1) [2025-05-12]. ISSN 2041-1723. PMC 11133479 . PMID 38806481. doi:10.1038/s41467-024-48780-6. （原始内容存档于2025-04-15）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiatry. 2024-08, 29 (8) [2025-05-12]. ISSN 1476-5578. PMC 11412894 . PMID 38486046. doi:10.1038/s41380-024-02498-5. （原始内容存档于2025-02-23）.
Wang, William; Wang, QuangQiu; Qi, Xin; Gurney, Mark; Perry, George; Volkow, Nora D.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2024-12, 20 (12) [2025-05-12]. ISSN 1552-5279. PMC 11667504 . PMID 39445596. doi:10.1002/alz.14313. （原始内容存档于2025-05-03）.
Sanyal, Arun J.; Newsome, Philip N.; Kliers, Iris; Østergaard, Laura Harms; Long, Michelle T.; Kjær, Mette Skalshøi; Cali, Anna M. G.; Bugianesi, Elisabetta; Rinella, Mary E.; Roden, Michael; Ratziu, Vlad. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England Journal of Medicine. 2025-04-30 [2025-05-12]. ISSN 1533-4406. PMID 40305708 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2413258.
McGuire, Darren K.; Marx, Nikolaus; Mulvagh, Sharon L.; Deanfield, John E.; Inzucchi, Silvio E.; Pop-Busui, Rodica; Mann, Johannes F. E.; Emerson, Scott S.; Poulter, Neil R.; Engelmann, Mads D. M.; Ripa, Maria Sejersten. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025-03-29 [2025-05-12]. ISSN 1533-4406. PMID 40162642 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2501006. （原始内容存档于2025-04-04）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024-01, 30 (1) [2025-05-12]. ISSN 1546-170X. PMC 11034947 . PMID 38182782. doi:10.1038/s41591-023-02672-2.

ncbi.nlm.nih.gov

Bliddal, Henning; Bays, Harold; Czernichow, Sébastien; Uddén Hemmingsson, Joanna; Hjelmesæth, Jøran; Hoffmann Morville, Thomas; Koroleva, Anna; Skov Neergaard, Jesper; Vélez Sánchez, Patricia; Wharton, Sean; Wizert, Alicja. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine. 2024-10-31, 391 (17) [2025-05-12]. ISSN 1533-4406. PMID 39476339. doi:10.1056/NEJMoa2403664. （原始内容存档于2025-03-17）.
Wang, Lindsey; Xu, Rong; Kaelber, David C.; Berger, Nathan A. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA network open. 2024-07-01, 7 (7) [2025-05-12]. ISSN 2574-3805. PMC 11227080 . PMID 38967919. doi:10.1001/jamanetworkopen.2024.21305. （原始内容存档于2025-02-20）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024-05-28, 15 (1) [2025-05-12]. ISSN 2041-1723. PMC 11133479 . PMID 38806481. doi:10.1038/s41467-024-48780-6. （原始内容存档于2025-04-15）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiatry. 2024-08, 29 (8) [2025-05-12]. ISSN 1476-5578. PMC 11412894 . PMID 38486046. doi:10.1038/s41380-024-02498-5. （原始内容存档于2025-02-23）.
Wang, William; Wang, QuangQiu; Qi, Xin; Gurney, Mark; Perry, George; Volkow, Nora D.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2024-12, 20 (12) [2025-05-12]. ISSN 1552-5279. PMC 11667504 . PMID 39445596. doi:10.1002/alz.14313. （原始内容存档于2025-05-03）.
Sanyal, Arun J.; Newsome, Philip N.; Kliers, Iris; Østergaard, Laura Harms; Long, Michelle T.; Kjær, Mette Skalshøi; Cali, Anna M. G.; Bugianesi, Elisabetta; Rinella, Mary E.; Roden, Michael; Ratziu, Vlad. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England Journal of Medicine. 2025-04-30 [2025-05-12]. ISSN 1533-4406. PMID 40305708 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2413258.
McGuire, Darren K.; Marx, Nikolaus; Mulvagh, Sharon L.; Deanfield, John E.; Inzucchi, Silvio E.; Pop-Busui, Rodica; Mann, Johannes F. E.; Emerson, Scott S.; Poulter, Neil R.; Engelmann, Mads D. M.; Ripa, Maria Sejersten. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025-03-29 [2025-05-12]. ISSN 1533-4406. PMID 40162642 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2501006. （原始内容存档于2025-04-04）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024-01, 30 (1) [2025-05-12]. ISSN 1546-170X. PMC 11034947 . PMID 38182782. doi:10.1038/s41591-023-02672-2.

dailymed.nlm.nih.gov

Ozempic- semaglutide injection, solution. DailyMed. [2021-06-05]. （原始内容存档于2021-06-05）.
Rybelsus- oral semaglutide tablet. DailyMed. [2021-06-05]. （原始内容存档于2021-06-05）.
Wegovy- semaglutide injection, solution. DailyMed. 2021-06-04 [2022-03-11]. （原始内容存档于2021-12-14）.

peptideshop.online

张文豹. Semaglutide for weight loss you need to know - semaglutide user guide. semaglutide user guide. 2024-04-29. （原始内容存档于2024-05-24）（美国英语）. |url-status=和|dead-url=只需其一 (帮助)

rxlist.com

Cunha JP (编). Side Effects of Wegovy (Semaglutide Injection), Warnings, Uses. RxList (part of the WebMD network). 2023-01-18 [2023-03-09]. （原始内容存档于2023-03-09）.

tga.gov.au

AusPAR: Semaglutide. Therapeutic Goods Administration (TGA). 2020-12-02 [2022-02-23]. （原始内容存档于2022-02-24）.
Rybelsus APMDS. Therapeutic Goods Administration (TGA). 2022-02-22 [2022-02-23].
WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd). Therapeutic Goods Administration (TGA). 2022-10-07 [2023-04-07]. （原始内容存档于2023-04-14）.

web.archive.org

AusPAR: Semaglutide. Therapeutic Goods Administration (TGA). 2020-12-02 [2022-02-23]. （原始内容存档于2022-02-24）.
Summary for ARTG Entry:315107 Ozempic 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen. Therapeutic Goods Administration (TGA). [2021-06-06]. （原始内容存档于2022-02-24）.
Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack. Therapeutic Goods Administration (TGA). [2022-02-23]. （原始内容存档于2022-02-24）.
WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd). Therapeutic Goods Administration (TGA). 2022-10-07 [2023-04-07]. （原始内容存档于2023-04-14）.
Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (报告). Novo-Nordisk Canada. 2020-08-21 [Initial approval 4 January 2018] [2021-06-06]. （原始内容存档 (PDF)于2021-06-07）.
Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (报告). Novo-Nordisk Canada. 2020-03-30 [2021-06-06]. （原始内容存档 (PDF)于2021-12-14）.
Regulatory Decision Summary – Rybelsus. Health Canada. 2014-10-23 [2022-06-04]. （原始内容存档于2022-06-05）.
Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC). (emc). 2021-04-09 [2021-06-06]. （原始内容存档于2021-06-06）.
Rybelsus – Summary of Product Characteristics (SmPC). (emc). 2020-11-25 [2021-06-06]. （原始内容存档于2021-06-06）.
Ozempic- semaglutide injection, solution. DailyMed. [2021-06-05]. （原始内容存档于2021-06-05）.
Rybelsus- oral semaglutide tablet. DailyMed. [2021-06-05]. （原始内容存档于2021-06-05）.
Wegovy- semaglutide injection, solution. DailyMed. 2021-06-04 [2022-03-11]. （原始内容存档于2021-12-14）.
Ozempic EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-09-26]. （原始内容存档于2020-10-25）.
Rybelsus EPAR. European Medicines Agency (EMA). 2020-01-29 [2020-09-26]. （原始内容存档于2020-08-14）.
Wegovy EPAR. European Medicines Agency. 2021-11-11 [2022-03-11]. （原始内容存档于2022-07-02）.
张文豹. Semaglutide for weight loss you need to know - semaglutide user guide. semaglutide user guide. 2024-04-29. （原始内容存档于2024-05-24）（美国英语）. |url-status=和|dead-url=只需其一 (帮助)
Bliddal, Henning; Bays, Harold; Czernichow, Sébastien; Uddén Hemmingsson, Joanna; Hjelmesæth, Jøran; Hoffmann Morville, Thomas; Koroleva, Anna; Skov Neergaard, Jesper; Vélez Sánchez, Patricia; Wharton, Sean; Wizert, Alicja. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine. 2024-10-31, 391 (17) [2025-05-12]. ISSN 1533-4406. PMID 39476339. doi:10.1056/NEJMoa2403664. （原始内容存档于2025-03-17）.
Wang, Lindsey; Xu, Rong; Kaelber, David C.; Berger, Nathan A. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA network open. 2024-07-01, 7 (7) [2025-05-12]. ISSN 2574-3805. PMC 11227080 . PMID 38967919. doi:10.1001/jamanetworkopen.2024.21305. （原始内容存档于2025-02-20）.
中国疾病预防控制中心. 华人团队发现，“减肥神药”司美格鲁肽或可显著降低阿尔茨海默病风险. 中国疾病预防控制中心科技文献服务系统. 2024-11-26 [2025-05-12]. （原始内容存档于2024-12-12）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024-05-28, 15 (1) [2025-05-12]. ISSN 2041-1723. PMC 11133479 . PMID 38806481. doi:10.1038/s41467-024-48780-6. （原始内容存档于2025-04-15）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiatry. 2024-08, 29 (8) [2025-05-12]. ISSN 1476-5578. PMC 11412894 . PMID 38486046. doi:10.1038/s41380-024-02498-5. （原始内容存档于2025-02-23）.
Apperloo, Ellen M.; Gorriz, Jose L.; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M.; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D.; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nature Medicine. 2025-01, 31 (1) [2025-05-12]. ISSN 1546-170X. doi:10.1038/s41591-024-03327-6. （原始内容存档于2025-04-30）（英语）.
Wang, William; Wang, QuangQiu; Qi, Xin; Gurney, Mark; Perry, George; Volkow, Nora D.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2024-12, 20 (12) [2025-05-12]. ISSN 1552-5279. PMC 11667504 . PMID 39445596. doi:10.1002/alz.14313. （原始内容存档于2025-05-03）.
McGuire, Darren K.; Marx, Nikolaus; Mulvagh, Sharon L.; Deanfield, John E.; Inzucchi, Silvio E.; Pop-Busui, Rodica; Mann, Johannes F. E.; Emerson, Scott S.; Poulter, Neil R.; Engelmann, Mads D. M.; Ripa, Maria Sejersten. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025-03-29 [2025-05-12]. ISSN 1533-4406. PMID 40162642 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2501006. （原始内容存档于2025-04-04）.
Cunha JP (编). Side Effects of Wegovy (Semaglutide Injection), Warnings, Uses. RxList (part of the WebMD network). 2023-01-18 [2023-03-09]. （原始内容存档于2023-03-09）.
医疗产品警报2024年第2期. 世界卫生组织. 2024-06-19 [2025-03-17]. （原始内容存档于2024-07-05）（中文）.

who.int

医疗产品警报2024年第2期. 世界卫生组织. 2024-06-19 [2025-03-17]. （原始内容存档于2024-07-05）（中文）.

worldcat.org

Bliddal, Henning; Bays, Harold; Czernichow, Sébastien; Uddén Hemmingsson, Joanna; Hjelmesæth, Jøran; Hoffmann Morville, Thomas; Koroleva, Anna; Skov Neergaard, Jesper; Vélez Sánchez, Patricia; Wharton, Sean; Wizert, Alicja. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine. 2024-10-31, 391 (17) [2025-05-12]. ISSN 1533-4406. PMID 39476339. doi:10.1056/NEJMoa2403664. （原始内容存档于2025-03-17）.
Wang, Lindsey; Xu, Rong; Kaelber, David C.; Berger, Nathan A. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA network open. 2024-07-01, 7 (7) [2025-05-12]. ISSN 2574-3805. PMC 11227080 . PMID 38967919. doi:10.1001/jamanetworkopen.2024.21305. （原始内容存档于2025-02-20）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024-05-28, 15 (1) [2025-05-12]. ISSN 2041-1723. PMC 11133479 . PMID 38806481. doi:10.1038/s41467-024-48780-6. （原始内容存档于2025-04-15）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiatry. 2024-08, 29 (8) [2025-05-12]. ISSN 1476-5578. PMC 11412894 . PMID 38486046. doi:10.1038/s41380-024-02498-5. （原始内容存档于2025-02-23）.
Apperloo, Ellen M.; Gorriz, Jose L.; Soler, Maria Jose; Cigarrán Guldris, Secundino; Cruzado, Josep M.; Puchades, Maria Jesús; López-Martínez, Marina; Waanders, Femke; Laverman, Gozewijn D.; van der Aart-van der Beek, Annemarie; Hoogenberg, Klaas. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nature Medicine. 2025-01, 31 (1) [2025-05-12]. ISSN 1546-170X. doi:10.1038/s41591-024-03327-6. （原始内容存档于2025-04-30）（英语）.
Wang, William; Wang, QuangQiu; Qi, Xin; Gurney, Mark; Perry, George; Volkow, Nora D.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2024-12, 20 (12) [2025-05-12]. ISSN 1552-5279. PMC 11667504 . PMID 39445596. doi:10.1002/alz.14313. （原始内容存档于2025-05-03）.
Sanyal, Arun J.; Newsome, Philip N.; Kliers, Iris; Østergaard, Laura Harms; Long, Michelle T.; Kjær, Mette Skalshøi; Cali, Anna M. G.; Bugianesi, Elisabetta; Rinella, Mary E.; Roden, Michael; Ratziu, Vlad. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England Journal of Medicine. 2025-04-30 [2025-05-12]. ISSN 1533-4406. PMID 40305708 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2413258.
McGuire, Darren K.; Marx, Nikolaus; Mulvagh, Sharon L.; Deanfield, John E.; Inzucchi, Silvio E.; Pop-Busui, Rodica; Mann, Johannes F. E.; Emerson, Scott S.; Poulter, Neil R.; Engelmann, Mads D. M.; Ripa, Maria Sejersten. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025-03-29 [2025-05-12]. ISSN 1533-4406. PMID 40162642 请检查|pmid=值 (帮助). doi:10.1056/NEJMoa2501006. （原始内容存档于2025-04-04）.
Wang, William; Volkow, Nora D.; Berger, Nathan A.; Davis, Pamela B.; Kaelber, David C.; Xu, Rong. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024-01, 30 (1) [2025-05-12]. ISSN 1546-170X. PMC 11034947 . PMID 38182782. doi:10.1038/s41591-023-02672-2.